Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.40 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.40 |
| ▸ | RPS17 | P08708 | 1/20 | 0.40 |
| ▸ | RPSA | P08865 | 1/20 | 0.40 |
| ▸ | RPS2 | P15880 | 1/20 | 0.40 |
| ▸ | RPL35A | P18077 | 1/20 | 0.40 |
| ▸ | RPL7 | P18124 | 1/20 | 0.40 |
| ▸ | RPL17 | P18621 | 1/20 | 0.40 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.40 |
| ▸ | RPS3 | P23396 | 1/20 | 0.40 |
| ▸ | RPS12 | P25398 | 1/20 | 0.40 |
| ▸ | RPL13 | P26373 | 1/20 | 0.40 |
| ▸ | RPL10 | P27635 | 1/20 | 0.40 |
| ▸ | RPL12 | P30050 | 1/20 | 0.40 |
| ▸ | RPL9; RPL9P7; RPL9P8; RPL9P9 | P32969 | 1/20 | 0.40 |
| ▸ | RPL22 | P35268 | 1/20 | 0.40 |
| ▸ | RPL4 | P36578 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082533 | 0.86 | L3MBTL1 (0.50) | CCR5MEN1KMT2AALDH1A1 | |
| SCHEMBL2084027 | 0.86 | CCR5 (0.40) | CCR5MEN1KMT2ARPLP1RPLP0 | |
| SCHEMBL4535370 | 0.84 | CCR5 (0.44) | CCR5MEN1KMT2ARPLP1RPLP0 | |
| SCHEMBL2084326 | 0.83 | CCR5 (0.48) | CCR5KMT2AKCNH2ALDH1A1 | |
| SCHEMBL2086498 | 0.82 | GRIN2B (0.54) | CCR5MEN1KMT2AALDH1A1NPSR1 | |
| Hydroxyamine SCHEMBL4518793 | 0.82 | CCR5 (0.43) | CCR5MEN1KMT2ARPLP1RPLP0 | |
| SCHEMBL2081000 | 0.82 | TDP1 (0.47) | CCR5KCNH2UBE2MDCUN1D1 | |
| SCHEMBL2082352 | 0.81 | SMO (0.43) | CCR5MEN1KMT2AKCNH2CYP2C19 | |
| SCHEMBL12935360 | 0.81 | CCR5 (0.41) | CCR5MEN1KMT2ARPLP1RPLP0 | |
| SCHEMBL2083744 | 0.80 | BTK (0.43) | CCR5MEN1KMT2AKCNH2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | claimed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | claimed |
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | CCR5 5/4885MEN1 4472/4885KMT2A 4082/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | CCR5 4/4885MEN1 4609/4885KMT2A 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.